Two pre-clinical studies carried out by leading dermatologist Dr. Riichiro Abe, Professor and Chair of Dermatology at Niigata University, indicate that PC111 monoclonal antibody can ease Stevens-Johnson Syndrome by eliminating excess of circulating Fas ligand.Severe...
Proprietary transgenic mouse produces human form of FasL protein May 4, 2023 – MILAN – PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two...
The biotechnology company has established a promising in-vivo platform for the development of its lead therapy, a monoclonal antibody that stops blistering in chronic skin conditions without suppressing the immune system. January 19, 2023 – MILAN –...
The nominations follow a successful seed funding led by Sofinnova Partners MILAN, Italy – May 6, 2020 – PinCell, a biotechnology company developing novel therapies for rare dermatological diseases, announced today the appointment of Gabriella Camboni,...
Il prof. Pincelli e la dottoressa Marconi hanno creato un farmaco contro il pemfigo che non deprime il sistema immunitario di Davide Berti – Gazzetta di Modena – 22.06.2015 – Ricerca, speranza e nuova cura. Sono queste le parole d’ordine. Due medici...
